Independently developed by Sichuan Biokin Pharmaceutical Co., Ltd., Izalontamab Brengitecan for Injection (Iza-Bren) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (bispecific ADC). It received its first NMPA approval in June 2026 for adult patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic chemotherapy plus PD-1/PD-L1 inhibitors, and previously obtained FDA Breakthrough Therapy Designation.

Many patients wonder: How long can CAR-T therapy last? Its long-term efficacy depends not only on the initial anti-tumor effect but also on the persistence of CAR-T cells in the body. Factors like T-cell quality, production process, tumor immune escape, and standardized whole-process management all affect outcomes. To improve durability, doctors recommend early intervention, optimized cell preparation, personalized targets, and long-term monitoring.

The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these longterm durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].